MBX Biosciences, Inc.
MBX Biosciences is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine and metabolic disorders live fuller and healthier lives. The company is focused on innovative science to address unmet needs in underserved markets through a growing pipeline of revolutionary precision endocrine peptides. Their mission is to improve the standard of care for endocrine and metabolic diseases by developing transformative medicines that are efficacious, safe, and accessible.
Industries
Nr. of Employees
small (1-50)
MBX Biosciences, Inc.
Carmel, Indiana, United States, North America
Products
Long-acting parathyroid hormone replacement candidate (once-weekly formulation)
Investigational, subcutaneously delivered peptide candidate engineered to provide continuous, infusion-like exposure to parathyroid hormone with the aim of restoring mineral balance and reducing dosing burden in hypoparathyroidism.
Peptide-based therapy for post-bariatric hypoglycemia
Investigational peptide therapy in development to prevent severe hypoglycemia in individuals who experience post-bariatric hypoglycemia, designed for convenient and sustained dosing.
Long-acting GLP-1/GIP receptor co-agonist candidate for obesity
Investigational long-acting peptide co-agonist targeting GLP-1 and GIP receptors developed to support weight loss and improve metabolic health with reduced dosing frequency and improved tolerability.
Long-acting parathyroid hormone replacement candidate (once-weekly formulation)
Investigational, subcutaneously delivered peptide candidate engineered to provide continuous, infusion-like exposure to parathyroid hormone with the aim of restoring mineral balance and reducing dosing burden in hypoparathyroidism.
Peptide-based therapy for post-bariatric hypoglycemia
Investigational peptide therapy in development to prevent severe hypoglycemia in individuals who experience post-bariatric hypoglycemia, designed for convenient and sustained dosing.
Long-acting GLP-1/GIP receptor co-agonist candidate for obesity
Investigational long-acting peptide co-agonist targeting GLP-1 and GIP receptors developed to support weight loss and improve metabolic health with reduced dosing frequency and improved tolerability.
Services
Collaborative drug discovery and development partnerships
Collaborative engagement with external partners to co-develop peptide therapeutic candidates and leverage internal discovery and development capabilities.
Clinical trial enrollment and patient support
Support for patient recruitment, trial information and engagement with advocacy groups for studies in endocrine and metabolic diseases.
Regulatory and CMC advisory support for peptide programs
Regulatory strategy planning and chemistry, manufacturing and controls advisory to advance peptide candidates through IND-enabling and clinical manufacturing activities.
Collaborative drug discovery and development partnerships
Collaborative engagement with external partners to co-develop peptide therapeutic candidates and leverage internal discovery and development capabilities.
Clinical trial enrollment and patient support
Support for patient recruitment, trial information and engagement with advocacy groups for studies in endocrine and metabolic diseases.
Regulatory and CMC advisory support for peptide programs
Regulatory strategy planning and chemistry, manufacturing and controls advisory to advance peptide candidates through IND-enabling and clinical manufacturing activities.
Expertise Areas
- Peptide therapeutics discovery and engineering
- Non-clinical pharmacology and toxicology
- Clinical trial management and operations
- CMC and pharmaceutical development
Key Technologies
- Peptide chemical modification
- Programmable prodrug technology
- Fatty-acylation half-life extension
- Design of long-acting receptor co-agonists